Distinct P2Y Receptors Mediate Extension and Retraction of Microglial Processes in Epileptic and Peritumoral Human Tissue


To cite this version:


HAL Id: hal-02530637
https://hal.sorbonne-universite.fr/hal-02530637
Submitted on 3 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Distinct P2Y receptors mediate extension and retraction of microglial processes in epileptic and peri-tumoral human tissue

Giampaolo Milior$^{1,2}$, Mélanie Morin-Brureau$^1$, Farah Chali$^1$, Caroline Le Duigou$^1$, Etienne Savary$^1$, Gilles Huberfeld$^{2,3}$, Nathalie Rouach$^2$, Johan Pallud$^4$, Laurent Capelle$^5$, Vincent Navarro$^5$, Bertrand Mathon$^5$, Stéphane Clemenceau$^5$ & Richard Miles$^1$

$^1$ Cortex & Epilepsie, Inserm U1127, CNRS UMR7225, UPMC Université Paris 6, Institut du Cerveau et de la Moelle épinière, Paris 75013, France. $^2$ Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Collège de France, CNR UMR 7241, INSERM U1050, Labex Memolife, PSL Research University, Paris 75005, France. $^3$ Clinical Neurophysiology Department, UPMC Université Paris 6, Hopital Pitié-Salpêtrière, AHP, Paris 75013, France. $^4$ Neurochirurgie, Hôpital Sainte-Anne, Paris Descartes University, IMA-BRAIN, Inserm, U894 Centre de Psychiatrie et Neurosciences Paris 75014, France. $^5$ Epilepsy Unit (VN), Neurochirurgie LC, BM, SC, AP-HP, Hôpital Pitié-Salpêtrière Paris, 75013, France.

Short title: Purines and motility of human microglia.

Correspondence should be addressed to: Dr Giampaolo Milior, College de France, 11 place Marcellin Berthelot, Paris 75005. giampaolo.milior@college-de-france.fr

Conflict of Interest: The authors declare they have no competing financial interests.

No of pages, 32. No of Figures, 8. No of extended Figures, 4. No of Movies, 7. No of Tables, 0.
ABSTRACT

Microglia exhibit multiple, phenotype-dependent motility patterns often triggered by purinergic stimuli. However, little data exists on motility of human microglia in pathological situations. Here we examine motility of microglia stained with a fluorescent lectin in tissue slices from female and male epileptic patients: mesial temporal lobe epilepsy (MTLE) or cortex surrounding glioma (PTC). Microglial shape varied from ramified to amoeboid cells predominantly in regions of high neuronal loss or closer to a tumor.

Live imaging revealed unstimulated or purine induced microglial motilities including surveillance movements, membrane ruffling and process extension or retraction.

At different concentrations, ADP triggered opposing motilities. Low doses triggered process extension. It was suppressed by P2Y12 receptor antagonists which also reduced process length and surveillance movements. Higher purine doses caused process retraction and membrane ruffling, which were blocked by joint application of P2Y1 and P2Y13 receptor antagonists.

Purinergic effects on motility were similar for all microglia tested. Both amoeboid and ramified cells from MTLE or PTC tissue, expressed P2Y12 receptors. A minority of microglia expressed the adenosine A2A receptor which has been linked with process withdrawal of rodent cells.

Laser-mediated tissue damage let us test the functional significance of these effects. Moderate damage induced microglial process extension which was blocked by P2Y12 receptor antagonists.

Overall, the purine-induced motility of human microglia in epileptic tissue is similar to that of rodent microglia in that the P2Y12 receptor initiates process extension. It differs in that retraction is triggered by joint activation of P2Y1/P2Y13 receptors.

KEY WORDS. live imaging, human microglia, purine, process extension, process retraction.

SIGNIFICANCE STATEMENT

Microglial cells are brain-resident immune cells with multiple functions in healthy or diseased brains. These diverse functions are associated with distinct phenotypes including different microglial shapes. In the rodent, purinergic signaling is associated with changes in cell shape such as process extension towards tissue damage. However, there is little data on living human microglia especially in diseased states. We developing a reliable technique to stain microglia from epileptic and glioma patients to examine responses to purines. Low intensity purinergic stimuli induced process extension, as in rodents. In contrast, high intensity stimuli triggered a process withdrawal mediated by both P2Y1 and P2Y13 receptors. P2Y1/P2Y13 receptor activation has not previously been linked to microglial morphological changes.
INTRODUCTION

Microglia are brain-resident immune cells with multiple functional phenotypes. In healthy tissue, ramified microglial processes move constantly to surveil the space around them (Dailey & Waite, 1999; Davalos et al., 2005; Nimmerjahn, Kirchhoff & Helmchen, 2005). During development, microglia remove superfluous synapses and cells to shape neuronal connectivity (Paolicelli et al., 2011; Schafer et al., 2012). In response to damage, microglial processes extend toward a site of injury and phagocytose cellular debris (Koizumi et al., 2007). In many pathologies, microglia liberate inflammatory mediators (Sanz & Di Virgilio, 2000; Bianco et al., 2005), but they also engage in repair and resolution (Raposo & Schwartz, 2014).

Distinct microglial phenotypes (Streit, Graeber & Kreutzberg, 1988) depend in part on signaling mediated by purinergic receptors (Hanisch & Kettenmann, 2007). Purines are released depending on neuronal activity and cell damage (Dale & Frenguelli, 2009). They act on ionotrophic P2X receptors (Khakh & North, 2012), on G-protein coupled P2Y receptors (von Kügelgen, 2006) and on adenosine receptors expressed by microglia (Chen, Lee & Chern, 2014). Distinct microglial phenotypes have been linked with activation of different purinergic receptors. Extension of processes towards an injury is mediated via P2Y12 receptors (Honda et al., 2001; Haynes et al., 2006). P2Y6 receptors trigger phagocytosis (Koizumi et al., 2007) and P2X7 receptors activate inflammasome processing of cytokines for secretion (Pelegrin et al., 2008).

Responses to purinergic stimuli differ for microglia in an inflammatory context and those in a healthy brain. While healthy cells extend processes towards a purine source or cell damage (Davalos et al., 2005; Haynes et al., 2006) processes of microglia in an inflamed brain retract. This difference has been attributed to a switch in receptor expression from P2Y12 to adenosine A2A receptors (Orr et al., 2009; Gyoneva et al., 2014). However motility patterns induced by purinergic stimulation have rarely been studied for human microglia in a pathological or inflammatory context.

We therefore examined the effects of purines on motility in microglia of tissue from patients with medial temporal lobe epilepsies and with epileptic cortical tissue surrounding or infiltrated by gliomas. A fluorescent lectin (Bordey & Spencer, 2003; Schwendele et al., 2012) was used to label microglia, enabling 2-photon imaging of living cells over several hours. In the absence of stimulation, microglia varied from round cells, through microglia with few processes to highly ramified cells (Boche, Perry & Nicoll, 2013; Morin-Brureau et al., 2018). We found purinergic stimuli induced distinct and opposing motility responses: extension at low doses and retraction of processes at higher doses. Our data suggest that extension was dependent on activation of P2Y12 receptors as in
the rodent. However process retraction was not mediated via A2A receptors (Orr et al., 2009), but
rather by joint activation of P2Y1 and P2Y13 receptors.

**MATERIALS AND METHODS**

*Tissue from epileptic patients*

We compared microglia in tissue from patients diagnosed with two syndromes. Temporal lobe tissue
was obtained after operations (CHU Pitié-Salpêtrière, Dr B Mathon, Dr S Clemenceau) on patients
diagnosed with pharmaco-resistant medial temporal lobe epilepsies associated with a hippocampal
sclerosis (MLTE; Le Duigou et al., 2018; Morin-Brureau et al., 2018). Tissue was obtained from 8 MTLE
patients (age 29-64, 4 women, 4 men, left or right temporal lobe sclerosis). Epileptic activities were
evident in surface EEG records and hippocampal sclerosis was confirmed by non-invasive imaging.
Cortical tissue was obtained from peri-tumoral regions (PTC) in patients diagnosed with cortical brain
tumors (CHU St Anne, Dr J Pallud; CHU Pitié-Salpetrière, Dr L Cappelle; Pallud et al., 2014). Cortical
tissue was obtained from 17 patients (age 25-63; 5 women, 12 men; 4 diagnosed with astrocytoma, 7
with glioblastoma, 7 with oligodendro-glioma; WHO grades I-IV). 7 of these 17 patients exhibited
seizures before surgery. Epileptic activities may have been missed in surface EEG records from the
other patients since sites of seizure generation are often restricted and /or deep in the brain.
Minimal cauterization during surgery enhanced the quality of tissue slices. Patients all gave a written,
informed consent. Protocols were approved by the Comité de protection des personnes, Ile de
France 1 (C16-16, 20152482) and followed guidelines of the Comité Consultatif National d’Ethique.

*Imaging of microglia in human tissue slices*

Tissue handling from the operating room to the laboratory was described in Le Duigou et al. (2018).
In brief, tissue was transported in a solution of: sucrose, 248; NaHCO₃, 26; KCl, 1; CaCl₂, 1; MgCl₂, 10;
d-glucose, 10 mM equilibrated with 95% O₂ and 5% CO₂, at 2–10 °C. Slices of thickness 300 µm were
cut in the same solution in sterile conditions with a vibrating tissue slicer (HM650V, Microm).
We tested two fluorophore-coupled lectins to stain microglia in acute human tissue slices for 2-
photon imaging. The B4 isolectin from Griffonia simplicifolia (GSA I-B4) labels fixed (Boya et al., 1991)
and living microglia (Petersen & Dailey, 2004) as does the tomato lectin from Lycopersicon
esculentum (Acarin et al., 1994; Bordey & Spencer, 2003). Staining was not detected further than
~50 µm from the slice surface, when tomato lectin conjugated to Dy-light 594 (Vector labs) or B4
isolectin conjugated to Alexa Fluor 488 (Thermofisher) were bath applied. We therefore injected
Lectins from patch pipettes inserted into middle regions of slices, at > 100 um from the surface.

Lectins were dissolved at 50 µM in a solution of NaCl, 150; KCl, 2.5 and HEPES 10 mM (pH 7.4, no added Ca^{++} or Mg^{++}) and ejected by gentle positive pressure applied for ~1 min.

Both the tomato lectin and B4 isolectin stained epithelial and endothelial cells of brain blood vessels (Fig. 1A). However only the tomato lectin provided useful staining of human microglia (Schwendele et al., 2012). This staining colocalized with Iba1 immunopositivity (Fig. 1B). Fluorescent microglia were resolved at 5-10 min after injection and strong signals were maintained during observations of duration up to 2-3 hrs. Possibly the tomato lectin also stains infiltrated peripheral monocytes and macrophages (Ravizza et al., 2008; Varvel et al., 2016). If so, lectin-positive elements, including cells associated with blood vessels, might be described as ‘tomato lectin positive cells’ (see Discussion).

We also used a fluorescent purine (EDA-ADP - ATTO-488, Jena Bioscience) to examine the clearance of purines from slices. It was dissolved in Tris-HCl (1 mM, pH 7.5) and the time course of the loss of fluorescence was compared after ejection into a tissue slice or into bath solution.

(Figure 1: Tomato lectin vs B4-isolectin. Microglial form)

2-photon imaging of microglia.

Fluorescent microglia were monitored with a Zeiss Axio Examiner Z1 microscope (Zeiss) using two-photon illumination (3i Intelligent Imaging) from a Chameleon Ultra II Ti-sapphire laser (Coherent).

Slices of human tissue were placed submerged in a chamber, perfused with a solution of: NaCl, 125; NaHCO_3, 26; KCl, 3; CaCl_2, 2; MgCl_2, 2 and glucose, 10 mM, equilibrated with 95% O_2 and 5% CO_2 and heated to 30-32 °C.

The Dy-light 594 coupled tomato lectin was excited at 800 nm and fluorescence detected by a photomultiplier tube with a 616/69 emission filter and a 580 nm dichroic mirror. IB4 isolectin was excited at 920nm and fluorescence detected after a 525/40 emission filter and a 580nm dichroic mirror.

Water immersion objectives of either 20x, NA 1.0 or 40x NA 1.0 (Zeiss) were used. Microglia were monitored after a delay of at least 90 min from slice preparation. Optical sections were collected at z-intervals 1-2 µm over a depth of 50-70 µm in the middle of slices. Complete z-stacks could be acquired at intervals of 30-60 sec. Images are shown as 2D projections of maximal intensity derived from z-stacks.

In some experiments laser stimuli were used to induce tissue damage. 10-20 pulses (duration 3 s, wavelength 720nm, power 400-500 mW) were delivered. Bright-field observations suggested damage was maximal in a zone of diameter ~10-15 µm at the targeted region.
Image analysis and quantification of microglial shape and motility.

Changes in microglial form were measured from sequentially obtained z-stacks with Slidebook software ((3i Intelligent Imaging). We attempted to minimize two possible sources of artefact. First, as microglial processes could overlap with those of lectin-stained blood vessels (Fig. 1C), or with those of other microglia during extension, we used minimal volumes of injected lectin to label few microglia. Second, since extending processes could extend beyond previously defined volumes, regions of interest were set to allow for process expansion.

The shape of identified, non-overlapping microglia was represented by a mask created on z-stack derived images. Median filtering and deconvolution with a ‘nearest-neighbour’ protocol (Slidebook) reduced noise and improved the resolution of fluorescent cells. Masks were created using a ‘segment mask’ tool, defined by Otsu thresholding (Slidebook). The ‘refine object’ tool was used for manual correction of threshold or shape, if needed. Finally the ‘mask statistics’ tool was used to follow the time course of changes in microglial cross sectional area (µm$^2$) derived from maximal 2-D projections from z-stacks. Cell volume was derived from complete 3-dimensional reconstructions of unstimulated single cells or maximally extended or retracted states after purinergic stimuli.

Ruffling, continuous extrusion and retraction of microglial surface membrane (Bianco et al., 2005), was quantified by subtracting sequential 2D maximal projections at defined time intervals. Color-coding of membrane lost or gained between sequential time points was used to illustrate process extension and retraction.

Purinergic stimulation of microglia: agonists and antagonists.

We examined microglial mobility and motility responses to bath application of purinergic agonists and antagonists. Slice preparation might alter the form and motility of human microglia. To reduce such possible artefacts, the effects of purines were not tested until at least 2 hr after slices were prepared. Response latencies were measured from the time of switching to the purine containing solution. Latencies include a delay of ~60 s for new solution to reach sites within a slice. Effects of purines on microglial processes were measured at a latency of 20 m after switching between solutions, unless noted otherwise.

Initial data was obtained with ADP (10 µM – 2 mM) and ATP (10 µM – 2 mM). Since purines are hydrolyzed by intrinsic tissue ecto-nucleotidases (from ATP to ADP to adenosine, Yegutkin, 2014), we also examined responses to a non-hydrolyzable ADP analog, 2MeSADP (2-methylthioadenosine diphosphate trisodium; 0.001-2 µM), a non-hydrolyzable ATP analog, 2MeSATP (2-
methylthioadenosine triphosphate tetra sodium, 0.1-100 µM) and the stable adenosine analog, 2-chloro-adenosine (10-100 µM). 2MeSADP is an agonist at P2Y1, P2Y12 and P2Y13 receptors.

2MeSATP is an agonist at P2Y1, P2Y6 and P2Y13 as well as P2X receptors. 2-chloro-adenosine is an agonist at A1, A2A, A2B and receptors (Abbracchio et al., 2019). We examined effects on these responses of specific antagonists at distinct purinergic and adrenergic receptors. As P2Y12 receptor antagonists we used PSB0739 (Tocris 0.1-5 µM; Baqi et al., 2009) and Ticagrelor (Cayman 1-10 µM; Cattaneo, 2010). MRS2279 (Tocris 1-10 µM; Shinozaki et al., 2014) and MRS 2500 (Tocris 1-10 µM; Quintas et al 2018) were used as antagonists at P2Y1 receptors. MRS2211 (Tocris 5-30 µM; Kim et al., 2005) was used as a P2Y13 antagonist. As A2A receptor antagonists we used Preladenant (Sigma 5 µM; Neustadt et al., 2009) and SCH-58261 (5 µM; Orr et al., 2009). MRS 2578 (Tocris 10 µM) was used as P2Y6 antagonist (Riegel et al., 2011).

**Immunostaining and imaging.**

Tissue slices (200-300 µm) were fixed for immunostaining by immersion for 2 min in PFA (4% phosphate-buffered paraformaldehyde) heated to 80°C. High temperatures enhance diffusion and accelerate fixation in slices (Dissing-Olesen & MacVicar, 2015). Immunostaining was performed on fixed slices (200-300 µm) washed in 0.1 M PBS (phosphate buffered saline) containing 20% DMSO (dimethyl sulfoxide) and 2% Triton x100. Slices were blocked in 3% BSA (24 hrs; bovine serum albumen) and then incubated with a primary antibody together with 1% BSA for 7 days at 4°C. We used primary antibodies directed against: Iba1 (Abcam, ab5076; 1/500), P2Y12 (Novus, NBP2-33870; 1/200) and A2AR (Santa Cruz, sc-32261; 1/100), P2Y1 (Abcam, ab168918; 1/200) and P2Y13 (LSBio, LS- A1622; 1/200). Slices were incubated for 6 days with secondary antibodies: IgG conjugated with Alexa 488, 555 or 647. These long exposures to primary and secondary antibodies should enhance penetration throughout fixed slices (Dissing-Olesen & MacVicar, 2015). After exposure slices were mounted in Fluorosave (Merck) on microscope slides with a cover glass elevated by 300 µm (Fisher Scientific).

Structured images were made with an Olympus IX81 fluorescent microscope equipped with filters for 4 emitted light wavelengths and visualized with Retiga EXI camera (Qimaging). Stacks of 10-30 images at z interval 0.5-1.0 µm were acquired with oil immersion objectives (40x, NA 1.3 or 60x, NA 0.9).
Experimental design and statistical analysis

Data are presented as mean ± SEM. Statistical analysis was done and graphs produced using Origin Pro 2016 software. The significance of differences between groups was assessed with the unpaired, two-sided Student’s t-test, with $p \leq 0.05$ considered significant. Differences within subjects were assessed with the paired, two-sided Student’s t-test with $p \leq 0.05$ considered significant.
RESULTS

Lectin labelled microglia in tissue from patients with mesial temporal lobe epilepsy (MTLE) and peri-tumoral cortex (PTC).

Tomato lectin labelled microglia in human MTLE and PTC tissue were heterogeneous in form, with features that were consistent between tissues. Fig. 1C shows examples of cells from PTC tissue and from the dentate, CA1 region and subiculum of MTLE-HS tissue. Three-dimensional reconstructions of these cells are shown in Fig. 1D and distributions of cross sectional area for cells from each region (n=21-58) are plotted in Fig. 1E.

Cells of the subiculum typically possessed multiple ramified processes similar to surveilling microglia of the rodent (Hanisch & Kettenman 2007). In contrast, microglia from the CA1 region where few neurons survived (Blümcke et al., 2013), were often smaller with fewer, shorter processes or no processes. Rodent cells with these shapes have been termed ‘activated’ and ‘reactive’ microglia (Streit, Graeber & Kreutzberg, 1988; Davis, Foster & Thomas, 1994). Initial work on human epileptic tissue identified many ‘reactive’ microglia (Beach et al., 1995). Microglia of peri-tumoral cortex exhibited a similar range of shapes. The density of tomato lectin positive cells with few processes was higher near the tumor (Buckingham & Robel, 2013). The cross-sectional area of cells with no processes, in MTLE and PTC tissue, was typically 70-180 µm². We will not differentiate between ‘reactive’ and ‘activated’ microglia, but rather class cells with cross-sectional areas < 300 µm² (red lines in Fig. 1E) and with two or less processes as amoeboid cells, and those with areas > 300 µm² and more than two processes as ramified (Buckingham & Robel, 2013; Morin-Brureau et al., 2018).

Responses of microglia to purinergic stimulation

We monitored fluorescent microglia in tissue slices from patients diagnosed with mesial temporal lobe epilepsies (MTLE) and in peritumoral slices from patients with cortical gliomas (PTC). In our previous work ~95% of MTLE tissues generate spontaneous interictal-like epileptic activity (Huberfeld et al., 2011) while such activity is recorded from ~70% of PTC tissue slices (Pallud et al. 2014).

Amoeboid microglia of MTLE or PTC tissue moved little in control conditions. Processes of ramified microglia of MTLE or PTC extended and retracted constantly while their somata moved little.

Different doses of ADP or ATP, applied by bath, induced opposing effects on microglial motility. Low doses (1-10 µM for 15-30 min) induced microglial process extension (Fig. 2A). Processes typically extended towards the surface of the slice and terminated in bulb-like endings (Fig. 2B). In amoeboid
cells application of 10 μM ADP (Fig. 2C; Movie 1) induced a significant increase of 80±18 % in cross-sectional area (p=0.004; t=-4.37; n=7, 3 MTLE and 4 PTC cells; Fig. 2E) transforming them into ramified cells. New processes appeared at a latency of 2-8 min (mean 5.0±1.2 min; Fig. 2G). The mean volume of amoeboid cells increased significantly from 296.5±34.5 µm³ to 555.8±106.9 µm³ at full extension (1 MTLE and 4 PTC cells; p=0.03; t=-3.23).

In ramified cells 10 μM ADP (Fig. 2D) also significantly increased mean cross-sectional area by 39±9 % (p=0.01; t=-3.42; 3 MTLE and 4 PTC cells; Fig. 2F). Process extension was initiated at a latency of 6-12 min (mean 9.4±1.4 min; n=3 MTLE and 4 PTC microglia). The latency to a 20% increase in cross-sectional area was consistently greater for ramified than for amoeboid microglia (p=0.009; t=3.2; Fig. 2G). The mean volume of ramified cells increased significantly from a control value of 709.2±74.3 µm³ to 900.2±30.4 µm³ at full extension (p=0.03; t=-3.17; n=5, 1 MTLE and 4 PTC cells; not shown).

Thus low doses of ADP induced process extension for both initially amoeboid and ramified microglia. Percentage increases in cross-sectional area and absolute increases in microglial volume were larger for amoeboid cells. Similar responses were induced by 10 μm ATP (n=5, 2 MTLE and 3 PTC cells not shown).

Higher doses of ADP or ATP (1-2 mM for 30 min) triggered distinct changes in microglial motility. Amoeboid cells exhibited ruffling (Fig. 3A; Movie 2), continuous advances and retraction often of perisomatic membrane (Bianco et al 2005), but 2 mM ADP induced only minor changes (mean 7±12%) in their cross-sectional area (p=0.6; t=-0.56; 3 MTLE cells, 4 PTC cells; Fig. 3E). Processes of ramified cells ceased surveillance movements in response to 2mM ADP. They then retracted with a latency of 5-10 min (mean 3.4±1.1 min; Fig. 3C; Movie 3). The cross-sectional area of ramified cells was reduced by 18±2% (p <0.001; t=6.04; 5 MTLE cells and 4 PTC cells; Fig. 3F). The volume of initially ramified cells was reduced significantly from 721.6±96.5 µm³ to 573.7±92.2 µm³ (p < 0.001, t=6.52; 5 MTLE and 2 PTC cells). Processes of initially ramified microglia did not retract so far as to convert them into amoeboid cells. Membrane ruffling occurred in ramified cells when retraction was complete. Cells tested with high dose ADP were not the same as those tested with low-dose ADP.
(Movie 3: process retraction of a ramified microglia induced by 2 mM ADP)

Unexpectedly process of both ramified and amoeboid microglia extended on switching from 2 mM ADP back to control ACSF (Fig. 3B, D). This rebound extension consisted of a significant increase (120±23 %) in cross-sectional area of amoeboid cells (p< 0.001; t=- 6.40, 3 MTLE cells, 4 PTC cells; Fig. 3E; Movie 2). This extension is comparable to that induced by 1-10 µM ADP. Rebound process extension occurred for all ramified microglia on switching to control ACSF (5 MTLE cells and 4 PTC cells; Fig. 3F; Movie 3). The mean increase in cross-sectional area at after ADP withdrawal was 31±5 % (p< 0.001; t=- 5.44). As for process extensions induced by low purine doses, the latency to rebound extension was consistently greater for ramified than for amoeboid microglia (p=0.002; t=3.86; Fig. 3G).

A similar process extension was induced on switching from 2 mM ADP to 10-50 µM ADP (n=4 cells not shown). This tends to suggest that the extension may have resulted from exposure to low levels of ADP during slow clearance from slices. We examined this possibility by comparing the decay of signals from a fluorescent purine (EDA-ADP - ATTO-488, 1mM) ejected from a patch pipette in the bath or in middle regions of a tissue slice. Signals decayed in 2-3 sec after ejection into the bath. In contrast, they decayed more slowly with a double exponential time course when ejection was made into the slice. Fluorescence levels at 20 min remained at 1.5-2 % of peak values. (Fig 3-1).

(Fig 3-1: clearance of a fluorescent purine from slices)

Intermediate purine doses (100-500 µM ADP, 15-30 min) could initiate either process retraction or extension in different neighboring cells. Fig. 2-1 plots dose/motility relations as percentage changes in cross-sectional area for 15 amoeboid and 16 ramified cells (1 µM to 2 mM ADP). Maximal mean increases in cross-sectional area (63±15 %; p=0.002, t=-4.1) occurred in response to 10 µM ADP. Maximal reductions (-16±5 %; p=0.009; t=3.10) were induced by 2 mM ADP. Process extension when purinergic stimulation ceased was most strong for 2 mM ADP. Fig. 2-1, C-E plots absolute changes in cross-sectional area for ramified and amoeboid cells showing a similar switch between process extension for low doses and retraction for high purine doses.

(Fig 2-1: changes in cross-sectional area for ADP doses of 2 µM–2 mM)

Overall these data show low and high doses of purines induce two distinct responses, microglial process extension and retraction comparable for ramified or amoeboid cells (Fig. 2-1,C-E).

Furthermore microglia of MTLE and PTC tissue tended to behave in the same way (Fig 2-2). Mean process extension induced by 10 µM ADP was 51 ±12 % in 4 ramified PTC cells and 42 ±3 % in 3 ramified MTLE cells (p=0.48; t=0.75; not significantly different; Fig 2-2, A). Process extension induced by low dose ADP was 92±27% for 4 amoeboid PTC cells and 67±14% for 3 amoeboid cells from MTLE.
tissue (p=0.61; t=0.53; not significantly different; Fig 2-2, B). Process retraction induced by 2 mM ADP was 18±4% for 4 ramified PTC cells and 13±3% for 5 ramified MTLE cells (p=0.72; t= -0.35; not significantly different; Fig 2-2, C). With these similarities, cells from PTC and MTLE tissues will be considered together in following data. (Fig 2-2: ADP effects on ramified and amoeboid microglia of PTC and MTLE tissue)

**Evidence for receptor expression.**

These opposing microglial motilities may depend on distinct receptors. In rodents, activation of the P2Y12 receptor initiates microglial process extension (Haynes et al., 2006). Reciprocally, purinergic stimuli induce process retraction by microglia in an inflammatory context (Gyoneva et al., 2014) via up-regulated A2A receptors (Orr et al., 2009).

Tissue from epilepsy patients is in an inflammatory state and some microglia have an amoeboid shape (Beach et al., 1995; Buckingham & Robel, 2013; Morin-Brureau et al., 2018). We therefore asked whether amoeboid or ramified cells of MTLE and PTC tissue express P2Y12 and A2A receptors by immunostaining with specific antibodies (Fig. 4). All Iba1+ cells in both types of tissue (Fig. 4A, B) were immunopositive to an antibody against P2Y12 receptors (Moore et al., 2015; Mildner et al., 2017). P2Y12 staining was detected, typically throughout microglia membrane and cytoplasm, for all amoeboid cells (n=25) and all ramified microglia (n=33) from MTLE-HS or PTC tissue (Fig. 4C).

In contrast, fewer Iba1+ microglia were immunopositive for A2A receptors and cellular staining was less uniform (Fig. 4A, B). A2A immunostaining was also evident outside microglia, suggesting the receptor was expressed by other cell types, unlike P2Y12 staining. A2A and Iba1+ immuno-staining were both detected in 13 of 25 amoeboid cells and 7 of 33 ramified microglia from a MTLE-HS or PTC tissue (Fig. 4C).

We also asked whether membrane distributions of these receptors altered during process extension or retraction induced by purinergic agonists. For microglia fixed in the resting state, P2Y12 receptor immunostaining was most intense at junctions between processes or towards process extremities (Fig. 4D). When slices were fixed after process extension induced by low doses of ADP, the highest intensities of immunostaining were detected at the bulbous tips of microglial processes (Fig. 4E).

(Figure 4: immuno: A2AR, P2Y12R. amoeboid cell, ramified microglial)
Purine receptor sub-type underlying process extension.

We sought pharmacological evidence that the activation of distinct purinergic receptors underlies extension or retraction of microglial processes. Receptor identification is not simple, since intrinsic tissue ecto-enzymes can hydrolyze ATP to ADP and ADP to adenosine (Yegutkin, 2014; Dale, 1998). We therefore used a non-hydrolyzable ADP analog, 2MeSADP (1 nM), which activates P2Y1, P2Y12 and P2Y13 receptors (Abbracchio et al., 2019). Fig. 5A shows 2MeSADP induced process extension of amoeboid microglia. 2MeSADP application significantly increased cross-sectional area by 49±9 % (p=0.01; t=-5.33 n=2 MTLE cells, 2 PTC cells), but did not provoke membrane ruffling (n=2 MTLE cells, 2 PTC cells).

Fig. 5B-D shows the effects of the specific P2Y12 antagonist PSB0739 (Baqi et al., 2009). At 0.1-1 µM, PSB0739 application led to a rapid cessation of surveilling movements (Fig. 5C; Movie 4) and the retraction of processes of ramified microglia (Fig. 5D; Movie 4). Cross sectional area was significantly reduced by 25±3 % after PSB0739 application, p=0.002; t=7.47; n=3 PTC cells, n=2 MTLE cells; Fig. 5B). This data suggests tonically activated P2Y12 receptors contribute to the control of process length and surveillance movements (Matyash et al., 2017). To confirm this point, we tested Ticagrelor, another P2Y12 receptor antagonist. Ticagrelor (1-5 µM; not shown) also suppressed surveillance movements of ramified cells. Cross-sectional area was significantly reduced by 27±5% by Ticagrelor (p=0.01; t=5.00; n=4 ramified microglia, all MTLE). Thus P2Y12 receptor antagonists suppress surveillance movements and reduce microglial process cross-sectional area to an extent comparable to 2mM ADP.

(Movie 4: PSB 0379 suppresses surveillance motility and blocks ADP-induced process extension)

We next asked whether PSB0739 (1 µM) or Ticagrelor (5 µM) affected process extension induced by 10 µM ADP (Fig. 5B; Movie 4). In 5 amoeboid microglia, increases in cross-sectional area were suppressed in the presence of PSB0739 (not shown). Similarly 10 µM ADP no longer induced extension of processes of ramified cells in the presence of PSB0739. The change in cross-sectional area for 7 cells was 5±3 % (p=0.13; t=-1.72; Fig. 5B; n=7; 5PTC, 2 MTLE; Fig. 7B). Process extension was also suppressed by Ticagrelor (5µM; n=3 cells; not shown) and extension observed on withdrawal of 2 mM ADP was also suppressed by PSB0739 (n=5 cells; not shown).

In summary, human microglia of amoeboid or ramified form, were all P2Y12+ (Fig. 5). Antagonists of these receptors blocked process extension and also suppressed surveillance movements revealing a tonic action of P2Y12 receptor activation.

(Figure 5: pharmacology of process extension)
Purine receptor sub-type initiating microglial ruffling and process retraction.

We asked whether adenosine receptor activation was involved in microglial process retraction or membrane ruffling induced by higher doses of purines. The stable broad-spectrum analog, 2-chloroadenosine (100 µM) was used to activate adenosine receptors. It induced a small reduction (8±10 %) in cross-sectional area of ramified microglia (p=0.46; t=0.79; 2 PTC, 4 MTLE cells; Fig. 6A), but did not induce membrane ruffling of amoeboid microglia (2 PTC, 4 MTLE cells).

Next we tested the effects of specific A2A receptor antagonists Preladenant and SCH58261 on the process retraction induced by 2 mM ADP. In 5 µM Preladenant, ADP application significantly reduced microglial cross-sectional area by 36±3% (p=0.001; t=10.33 n=4 PTC cells Fig. 6B). Similarly SCH58261 (5 µM) did not prevent process retraction induced by ADP. 2 mM ADP reduced cross sectional area by 47±9% in the presence of SCH58216 (p=0.03; t=5.13; 3 PTC microglia). In summary, not all microglia, including amoeboid cells, express A2A receptors (Fig. 5). Antagonists of these receptors did not suppress process retraction induced by strong purinergic stimuli.

If adenosine receptors are not involved in process retraction, might P2Y receptors be responsible? We turned to another broad spectrum agonist, the non-hydrolyzable ATP analog, 2MeSATP which activates P2Y1, P2Y13 and P2Y6 but not P2Y12 receptors (Abbracchio et al., 2019). 2MeSATP (100 µM) reduced microglial cross-sectional area significantly by 31±6% (p=0.04; t=4.73; 3 ramified PTC microglia; Fig. 6C). Membrane ruffling was initiated in all 3 amoeboid PTC microglia tested.

These data suggest that 2MeSATP activates a distinct purinergic receptor which is responsible for the effects of strong ADP stimuli. In experiments with specific P2Y receptor antagonists, we found the P2Y6 antagonist MRS 2578 (10 µM) did not block the ADP 2mM induced process retraction (4 ramified PTC cells, not shown). The P2Y1 antagonists MRS2179 (5-10 µM) and MRS2500 (10 µM) did not suppress process withdrawal. A reduction of 33±5 % in mean cross-sectional area was induced by 2 mM ADP in the presence of the antagonists (p=0.002; t=6.50; n=5, 3 MTLE and 2 PTC cells; Fig. 6D). The P2Y13 antagonist MRS2211 (10 µM) did not suppress ADP mediated retraction of processes of ramified cells. Mean cross-sectional area was reduced by 31±6 % by 2 mM ADP application in the presence of MRS2211 (p=0.01; t=4.97; n=4 PTC cells; Fig. 6E). Furthermore membrane ruffling induced in amoeboid microglia by 2 mM ADP persisted in the presence of MRS2211 (n=4 PTC cells).

However, joint application of P2Y1 and P2Y13 antagonists suppressed process retraction (MRS2500 and MRS2211; Fig. 6F, G; Movie 5). In the presence of both antagonists, mean cross section area changed by only 5±7 % in response to 2 mM ADP (p=0.18; t=1.62; n=5 ramified cells; 2 MTLE, 3 PTC microglia Fig. 6G). In 3 of 5 initially ramified cells, some microglial processes retracted and others...
extended but overall cross sectional area was little changed. Microglial perisomatic volume tended to increase (Fig. 6G) and membrane ruffling was suppressed in the presence of both antagonists. 

\[(\text{Figure 6: pharmacological basis of high-dose process retraction})\]

\[(\text{Movie 5: Co-application of P2Y1 and P2Y13 receptor antagonists suppresses process retraction})\]

We next sought anatomical support for a possible role of P2Y1 and P2Y13 receptors in microglial process retraction using immunohistochemistry to test their expression in microglia. Microglia were identified by Iba1 immunostaining together with P2Y1 and P2Y13 receptor antibodies (Methods). Expression was examined for 95 Iba1+ cells (47 ramified, 48 amoeboid) in 6 PTC slices from 3 patients (Fig 6-1). P2Y1+ immunostained 70 % of Iba1+ cells (76% ramified, 62% amoeboid cells). P2Y13 immunopositivity was expressed by 63 % of Iba1+ cells (80% ramified, 45% amoeboid cells). Both P2Y1 and P2Y13 immunostaining were detected outside Iba1+ cells, suggesting other cell types may express these receptors. 

\[(\text{Fig 6-1: P2Y1, P2Y13 immunohistochemistry on microglia})\]

**Microglial process extension and retraction in response to neuronal ablation.**

Finally we used laser ablation to examine the effects of tissue damage on the process motility of local microglia (Davalos et al., 2005; Eyo et al., 2014). Since damage induces purine release (possibly with other mediators), this approach let us test the legitimacy of pharmacological data. Bright field images from targeted regions with initially visible neurons were examined before and after stimulation to monitor effects of laser ablation.

In response to laser damage all microglia (4 amoeboid and 3 ramified PTC and MTLE cells) extended 1-3 novel processes. They projected 15-30 µm towards the damage site and encircled the damaged region (Fig. 7A; Movie 6). As in responses to ADP, the tips of extending processes terminated in bulbous endings. Phagocytic cup-like structures were sometimes apparent. Process extension was initiated at ~3 min after laser stimulation and ceased at ~10 min. Mean microglial cross sectional area increased by 52± 14 % ( p= 0.01; t=-3.62; 7 PTC and MTLE cells). This convergence of extending microglial processes resembles responses to neuronal damage (Petersen & Dailey, 2004), NMDA receptor activation (Dissing-Olesen et al., 2014) or low calcium levels (Eyo et al., 2015).

We next examined the effects of the P2Y12 antagonist PSB 0739 (1 µM) on process extension induced by laser damage (4 initially amoeboid cells PTC, 3 ramified cells, PTC). PSB 0739 induced process retraction and membrane ruffling (as Fig. 5B). A further laser stimulation at the same site, in
the presence of the antagonist, no longer triggered process extension, but rather retraction and membrane ruffling (4 amoeboid and 3 ramified cells, PTC; Fig. 7B; Movie 6).

If the P2Y12 antagonist suppresses process extension towards a damaged site, extension should be restored in its absence. We tested this point with a second stimulation at the same site with observations on 4 PTC and 2 MTLE cells. In response to the second laser stimulus, mean process cross sectional area increased by 47± 18 % (p= 0.04; t= -2.57; 4 PTC cells, 2MTLE cell; Movie 7). The movie shows processes with bulbous endings at their tips approach and encircle the damaged site.

(Figure 7: microglial process responses to laser ablation)

(Movie 6: Local laser damage induces process extension, blocked by P2Y12R antagonist)

(Movie 7: Process extension restored in the absence of P2Y12R antagonist)
DISCUSSION

This work examined purinergic effects on processes of microglia from patients with MTLE and with glioma, both associated with an inflammatory state. Purines induced process extension at low doses and process retraction at higher doses. Process extension, for both ramified and amoeboid microglia, resulted from the activation of P2Y12 receptors. Laser induced tissue damage reproduced microglial process extension. P2Y12 receptors also tonically promoted microglia process surveillance movements. Our data suggest joint activation of P2Y1 and P2Y13 receptors underlies process retraction and ruffling behaviors initiated by higher intensity purinergic stimuli.

Microglia in a pathological context: response to low and high intensity purinergic stimuli

Immunostaining showed most, possibly all, MTLE and PTC microglia expressed the P2Y12 receptor, which triggers process extension in rodents (Haynes et al., 2006; Ohsawa et al., 2010; Dissing-Olesen et al., 2014). A minority of microglia were immuno-positive for the A2A receptor which we supposed might initiate process retraction (Orr et al., 2009; Gyoneva et al., 2014). Motility responses were consistent with these data. Process extension by both ramified and amoeboid microglia initiated by weak purinergic stimuli was suppressed by antagonists of P2Y12 receptors. Process retraction induced by stronger stimuli was not suppressed by A2A receptor antagonists, but was blocked by joint application of P2Y1 and P2Y13 receptor antagonists.

In rodents, surveilling, ramified cells and amoeboid, ‘activated’ microglia respond differently to purinergic stimuli. Microglia ‘activated’ by lipopolysaccharide (LPS) treatment, retract rather than extend their processes. Microglial expression of P2Y12 receptors is down-regulated after LPS treatment (Haynes et al 2006; Orr et al., 2009). A2A receptors are up-regulated and trigger retraction (Gyoneva et al 2014; Orr et al., 2009). Our data shows microglia in tissue from patients with MTLE or gliomas do not behave in this way.

How similar are the phenotypes of ‘activated’ human epileptic microglia and LPS-treated rodent cells? Microglia of epileptic human tissue were first classed as ‘reactive’ according to shape and inflammatory marker expression (Beach et al., 1995). We now know seizures release inflammatory molecules (Vezzani et al., 1999; Morin-Brureau et al., 2018) and rupture the blood-brain barrier (Cornford, 1999; Cacheaux et al., 2009) permitting entry of systemic immune cells. Our data showed microglia of the CA1 region in MTLE tissue or closer to the tumor in PTC tissue were more likely to possess an ‘activated’ shape with few or no processes. However P2Y12 receptor expression by cells of all shapes (Fig. 4) seems inconsistent with other human data. Microglia close to lesions in tissue of
multiple sclerosis patients (Mildner et al. 2017; Zravy et al., 2017) or near amyloid tangles in patients with Alzheimer’s disease (Mildner et al., 2017) show little or no P2Y12 immunostaining. We note the antibody used here recognizes the same 40-amino acid cytoplasmic region of the receptor as that used by Mildner et al. (2017). Data showing all lba1+ elements were P2Y12+ (cf. Mildner et al. 2017) suggests that cells studied here were microglia rather than infiltrating immune cells.

However microglia ‘activated’ in different contexts may exhibit distinct motility patterns and express different receptors. ‘Alternatively activated’ human microglia, treated with interleukins IL-4 and IL13 rather than LPS, show more intense immunostaining against P2Y12 and respond more strongly to ADP (Moore et al., 2015). ‘Alternatively activated’ microglia are linked to repair processes, as transcriptomic data from the CA1 region of MTLE tissue suggests (Morin-Brureau et al., 2018). In kainite-treated epileptic mice, ‘activated’ microglia continue to extend processes towards purinergic stimuli or cellular damage (Avignone et al., 2015). The phenotype of ‘activated’ microglia in human epileptic brain may not be identical to that of LPS-treated rodent cells.

**P2Y12R: Microglial process extension and basal effects on surveillance.**

We found few differences between ramified and amoeboid microglia in the process extension induced by low intensity purinergic stimuli (Haynes et al., 2006; Ohsawa et al., 2010; Dissing-Olesen et al., 2014). Increases in cross-sectional area were large, 80-100 % for initially amoeboid cells, possibly mediated by endocytic membrane recycling (Kay et al., 2008). Processes were directed towards purinergic stimuli and P2Y12 receptors moved toward growth sites (Dissing-Olesen et al., 2014). Microglia of MTLE and PTC tissue exhibited similar motility responses. Similar, even though ambient glutamate levels in PTC are higher than in MTLE tissue (Buckingham et al., 2011) and mitosis and cell cycle-related molecules are upregulated in peritumoral microglia (Szulzewsky et al. 2016). Specific tumor associated macrophages may have immunosuppressive effects in glioblastoma (Chen & Hambardzumyan, 2018) and immune related transcripts of human microglia (Szulzewsky et al., 2016) are not notably upregulated in glioblastoma tissue.

Actions of the antagonists PSB0739 and Ticagrelor, suggests tonic activation of the P2Y12 receptor promotes non-directed surveillance movements. Similar conclusions have emerged from work on spinal microglia of mice genetically deficient for the P2Y12 receptor (Gu et al., 2016), but not from rodent hippocampal microglia treated with receptor antagonists (Madry et al., 2018). A role for P2Y12 receptors in directed extension of rodent microglial processes is generally agreed (Haynes et al., 2006; Madry et al., 2018). although adenosine receptors may also need to be activated (Matyash et al., 2017). Pathways linking P2Y12 receptor activation to process extension remain to be
completely described. This receptor is coupled to G\textsubscript{i} (Erb & Weisman, 2012; Abbracchio et al., 2019). Activation inhibits adenylate cyclase, increases internal Ca and induces K-currents. Those mediated by the 2-pore channel, THIK1, contribute to surveillance movements but not process extension (Madry et al., 2018). Akt, a Ca-dependent kinase, activates beta1 integrins facilitating process extension by interactions with the extracellular matrix (Somanath et al 2007; Ohsawa et al, 2010).

The PI3k pathway has been implicated in purine-induced chemotaxis (Wu, Vadakkan & Zhuo, 2007). Small GTPase pathways are crucial modulators of cytoskeletal actin remodeling (Sadok & Marshall, 2014; Rottner et al., 2017) but their involvement in microglial process extension is not clear.

**P2Y1/P2Y13: joint effects on microglial process retraction and ruffling**

Our data suggest that P2Y1 and P2Y13 receptors are involved in microglial process retraction induced by high dose purinergic stimuli, the same as used previously in rodents (Madry et al., 2018; Eyo et al., 2014). Ramified cells of both MTLE and PTC behaved similarly. In contrast to extension which was directed, retraction was non-directional. Membrane ruffling of ramified and amoeboid cells, induced by high intensity stimuli was also suppressed by simultaneously applied P2Y1 and P2Y13 antagonists.

Neither P2Y1 nor P2Y13 receptors have been linked to microglial process retraction. The P2Y1 receptor is coupled to G\textsubscript{q} and activates phospholipase C as well as the small GTPases Rac and Rho (Erb & Weisman, 2012; Abbracchio et al., 2019). The P2Y13 receptor is strongly homologous to P2Y12, coupled to the same G\textsubscript{i} and also inhibits adenylate cyclase as well as RhoA, a small GTPase. Links between P2Y1 and P2Y13 receptors, actin filament remodeling and process retraction remain to be explored.

The finding that both P2Y1 and P2Y13 antagonists were needed to suppress process retraction might imply a synergy between signaling pathways initiated by distinct receptors or rather reflect the activation of a single receptor entity. Precedents exist for either possibility. For instance, there is reciprocal cross-talk between intracellular pathways activated by P2Y1 and P2Y12 receptors in platelets (Hardy et al., 2004). Alternatively, distinct G-protein coupled receptors may express as dimers (Gurevich & Gurevich, 2008). P2Y1 receptors form heteromers with both P2Y11 (Ecke et al., 2008) and A1R adenosine receptors (Yoshioka, Saitoh & Nakata, 2001). Immunostaining data (Extended Fig. 4) suggested that P2Y1 and P2Y13 were expressed at higher levels in ramified than amoeboid microglia but not universally, unlike P2Y12 receptors. Staining could seem to overlap on Iba1+ cells, raising the possibility that both antibodies recognized receptors involved in retraction.
Our data on microglial process movements induced by focal tissue damage reinforces results from purine applications, although we did not measure levels of purines or adenosine (Laudet et al., 2005). Epileptiform activity induced in slices causes adenosine increases in the range of 10 µM with smaller changes in ATP (Frenguelli & Wall, 2016). Extracellular purine levels may be much higher after brain damage in part due to ATP release from astrocytes (Franke, Krügel & Illes P, 2006; Choo et al., 2013).

Microglia adopt shapes ranging from ‘reactive’ ovoid cells through ‘activated’ microglia with large soma and some thick processes to highly ramified cells (Fig. 8). We suggest that purinergic signaling could partially, but not completely, underlie cycling of a given cell through these different shapes and back again (Hanisch & Kettenmann, 2007; Yamada & Jinno, 2013; Jonas et al., 2012). Specifically, weak ADP stimuli, and cell damage, induce strong process extension by amoeboid or even round microglia. However process retraction of highly ramified cells exposed to high purine levels does not produce completely amoeboid cells, but rather microglia with shorter ramifications.

In conclusion, we have implemented live imaging of microglia in tissue from patients with temporal lobe epilepsy and cortical glioma. Cell shape varied from highly ramified microglia to cells with few or no processes. Low levels of purinergic stimuli intensity induced process extension of all microglia mediated via P2Y12 receptors. Higher purine doses induced retraction of ramified microglial processes and membrane ruffling which were suppressed by joint application of P2Y1 and P2Y13 receptor antagonists.
FIGURE LEGENDS

Figure 1. Staining and form of microglia in human peritumoral cortex and temporal lobe.

A. Staining of peritumoral cortex with IB4 lectin (green, left), tomato lectin (red, middle) and both signals (merge). Maximal intensity from z-stack (total 50 µm, step 1 µm) at 10 min after focal injection of lectins. IB4 lectin stained only endothelial cells of blood vessels (BV). Tomato lectin stained both microglia and endothelial cells. B, Tomato lectin positive cells (right) were also Iba1+ (left). C. Tomato lectin labeled microglia from peritumoral cortex and from the CA1, dentate and subicular regions of MTLE tissue. Maximal intensity from z-stacks (50 µm, 1 µm step). D. 3-D reconstructions of cells in C. Cross-sectional area at upper right. E. Cross sectional area distributions for cells of peri-tumoral cortex (n=34) and CA1 (n=25), dentate gyrus (n=17) and subiculum (n=18 cells) of MTLE tissue. The red line is the threshold of 300 µm² used to distinguish amoeboid and ramified cells.

Figure 2: At low doses ADP induces microglial process extension

A. Tomato lectin stained PTC microglia before (CTRL, left) and after bath application of ADP (10 µM, 15 min, right). Change maximal cross sectional area are shown in red. (z-stacks 50 µm, 1 µm). B. Lateral view shows microglial processes extended toward the upper surface of the slice. Red arrows show bulbous endings at their tips. C. ADP at low doses induces process emergence and extension from an amoeboid cell. Images are control (CTRL, left) and ADP (10 µM, 15 m, middle). Merge (right) shows color-coded differences between CTRL and ADP images. Red, new signal; green, lost signal; yellow, maintained signal (z-stack 20 µm, 1 µm). Inset at right shows bulbous endings (red arrow) at the tips of processes. D. ADP induces process extension of a ramified microglia. Control (CTRL, left), ADP (10 µM, 15 min middle) and color-coded differences between them (Merge, right). Red, new signal; green, lost signal; yellow, maintained signal. (z-stack 20 µm, 1 µm). The inset shows bulbous endings (red arrow) at process tips. E. Time course of changes in mean cross-sectional area induced by 10 µM ADP in 7 amoeboid microglia. F. Time-course of changes in mean cross-sectional area induced by 10 µM ADP in 7 ramified microglia. G. Mean and s.e. of the latency to 20 % increase in cross sectional area induced by ADP for amoeboid (n=7) and ramified microglia (n=7). Process extension by ramified cells occurred at a significantly longer latency (t-test, p=0.009).

Figure 2-1 shows the changes in cross-sectional area for ADP doses of 2 µM–2 mM. Figure 2-2 shows the ADP effects on ramified and amoeboid microglia of PTC and MTLE tissue. Movie 1 shows process extension of an amoeboid cell induced by low-dose ADP.
**Figure 2-1: Dose-response for process motilities induced by ADP**

**A.** Percentage changes in microglial cross-sectional area induced by ADP (1 µM – 2 mM). Ramified cells, filled diamonds; amoeboid microglia, open squares. Extension was maximal for 10 µM ADP. **B.** Changes of cross-sectional area on ADP washout for initially ramified (filled diamonds) and initially amoeboid cells (open squares) plotted as percentage change from area under ADP. Minor process extensions only were detected after exposure to ADP levels less than 2 mM. Absolute changes in microglial cross-sectional area induced by, **C.** 1-10 µM, **D.** 100-500 µM, and, **E.** 2 mM ADP. Dashed line at 300 µm^2 is the threshold separating amoeboid and ramified microglia. Amoeboid and ramified cells behaved in a similar way.

**Figure 2-2: ADP effects on ramified and amoeboid microglia of PTC and MTLE tissue**

**A.** 10 µM ADP induces similar process extensions for ramified microglia of PTC (n=4) and MTLE tissue (n=3). **B.** Low dose ADP (10 µM) induces comparable process extensions for amoeboid cells of PTC (n=4) and MTLE tissue (n=3). **C.** 2 mM ADP induces similar process retractions for ramified microglia of PTC (n=4) and MTLE (n=5) tissue. Mean responses of MTLE cells shown as open squares and PTC cells as filled squares.

**Figure 3: High doses of ADP induce microglial process retraction and membrane ruffling.**

**A.** ADP induces membrane ruffling of an amoeboid microglia. Control (left), ADP (2 mM, 20 min, middle). Merge (right) shows color-coded differences. Red, new fluorescent signal; green, lost signal; yellow, maintained signal. **B.** Transition from 2 mM ADP back to control for the same cell (wash, left), induces process extension. Merge (right) shows differences from ADP. Blue, new signal; red, lost signal. **C.** ADP induces process retraction and membrane ruffling of a ramified microglia. Control (left), ADP (2 mM, 20 min, middle). Merge (right) shows differences. Blue, new signal; green, lost signal; yellow, maintained signal. **D.** Transition from ADP back to control for the cell in **C** induces process extension (wash, left). Merge image (right) shows blue, new signal; red, lost signal. **A-D** are all maximal projections from z-stacks (50 µm, 2 µm step). **E.** Time course of changes in mean cross-sectional area in 7 initially amoeboid cells. Little change occurs during application of 2 mM ADP application. Processes extend when ADP is removed. **F.** Time course of the reduction in mean cross-section.
sectional area induced by 2 mM in 9 ramified microglia. G. Different latencies to process extension (increase of 20 % for cross sectional area) during the transition from 2 mM ADP back to control ACSF. The latency is significantly longer for ramified microglia (t-test, p=0.004). Figure 3-1 shows the clearance of a fluorescent ADP from the slice. Movie 2 shows membrane ruffling of an amoeboid microglia induced by 2 mM ADP. Movie 3 shows process retraction of a ramified microglia induced by 2 mM ADP.

Figure 3-1: Fluorescent ADP clearance from the slice

A. Fluorescence at 0, 5, 10, and 20 min after focal ejection of the fluorescent purine EDA-ADP - ATTO-488 at 1 mM from a patch pipette into middle regions of a 300 μm thick PTC slice. B. Typical time course for the decay of fluorescence, measured as whole screen fluorescent signal. C. The decay followed a double exponential time course with fastest decay in the first 3-5 min. The fit was y = 435.0*exp(-x/0.9) + 158.9*exp(-x/3.4) + 14.6, where y is fluorescence and x is time. Fluorescence was maintained longer than 20 min after ejection into the slice, but decayed in 2-3 sec after ejection into the bath.

Figure 4: Expression of P2Y12 and A2A receptors by human microglia.

A. Immunostaining against P2Y12 and A2A receptors in an IBA1+ ramified PTC microglia. B. P2Y12 and A2A receptor immunostaining for an amoeboid IBA1+ cell from MTLE tissue. Panels in A and B are from the left: P2Y12 immuno-staining (green), IBA1 (white), A2A (red) and merged P2Y12 and A2A staining. C. Proportion of ramified (clear; n=33) and amoeboid (hatched; n=25) microglia immuno-positive for P2Y12 (gray) and A2A receptors (red). D. Color-coded staining intensity (green, low – red, high) shows P2Y12 staining was highest towards the tips of processes of a ramified microglia (above) in the resting state. Intensity was highest in a somatic region of a non-stimulated amoeboid cell (below). E. Color-coded intensity (green low – red high) for P2Y12 immunopositivity for an initially amoeboid microglia fixed at full extension induced by 10 μM ADP. Staining intensity was low in peri-somatic regions (above) and highest at bulbous endings of processes (below).

Figure 5: P2Y12 receptors and microglial motilities.

A. The non-hydrolyzable ADP analog, 2MeSADP (1 nM) increased mean microglial cross sectional area (n=4 PTC cells). B. The P2Y12 receptor antagonist PSB0739 (1 μM) reduced the mean cross-sectional area of ramified microglia (3 PTC and 2 MTLE microglia). It prevented the process extension induced by 10 μM ADP. C. PSB0739 suppressed surveillance motility of processes of a ramified
Figure 6: Receptors involved in microglial process retraction.

A. The stable adenosine analog 2-chloro-adenosine (100 µM) induced a small reduction in mean microglial cross-section area (4 MTLE and 2 PTC ramified cells). B. The A2A receptor antagonist, Preladenant (5 µM) did not suppress process retraction induced by 2 mM ADP (n=4 ramified PTC cells). C. The non-hydrolyzable ATP analog, 2MeSATP (100 µM) reduced the mean cross sectional area of 3 ramified microglia of MTLE tissue. D. P2Y1 receptor antagonists MRS2500 or MRS2179 (10 µM) did not prevent the reduction of microglial cross-sectional area induced by 2 mM ADP in ramified microglia (4 MTLE, 2 PTC cells). E. The P2Y13 antagonist MRS2211 (30 µM) did not suppress process retraction induced by 2 mM ADP in 4 ramified PTC microglia. F. Co-application of MRS2500 (10 µM) and MRS2211 (30 µM) suppressed retraction induced by 2 mM ADP 2mM (5 ramified cells; 2 MTLE, 3 PTC cells). G. Response of an initially ramified microglia (PTC) to 2 mM ADP in the presence of MRS2500 (10 µM) and MRS2211 (30 µM). From the left CTRL, basal state, in the presence of both antagonists and then 2 mM ADP. The merge image shows the difference between cell shape in the presence of both antagonists and then after applying ADP. New fluorescent signal, green; lost signal red; maintained signal, yellow. Figure 6-1 shows the immunohistochemistry for P2Y1 and P2Y13 receptors on fixed slices. Movie 5 shows that the co-application of P2Y1 and P2Y13 receptor antagonists suppresses process retraction.

Figure 6-1: P2Y1 and P2Y13 immunostaining

A. Immunostaining against P2Y1 and P2Y13 receptors in an IBA1 + microglia (amoeboid cell of PTC). B. P2Y1 and P2Y13 receptor immunostaining for a ramified PTC cell. Panels in A and B are from the left: lba1 staining (green), P2Y1 staining (blue), P2Y13 staining (red) and merge of P2Y1, P2Y13 and lba1 staining. Arrows indicate the spatial overlap of P2Y1 and P2Y13 staining in lba1+ cells in both A and B. Such overlap was seen in 47 % (45/95) of lba1+ microglia C. Ramified cells (n=47) were more likely than amoeboid cells (n= 48) to be immunopositive for P2Y1 (blue) or P2Y13 receptors (red).
Figure 7: Role of P2Y receptors in microglial motility induced by tissue damage.

A. The effects of local laser stimulation. Control images of an initially amoeboid cell from peri-tumoral cortex before (CTRL), immediately after laser damage (yellow arrow) and at 10 and 15 min later. Merge is the difference between control and +15 min images. New membrane signal in red, lost signal in green. B. The same cell after a second laser stimulus (yellow arrow) applied 5 min after the P2Y12 antagonist PSB 0739 (1 µM). Images are shown at 5 and 15 min after stimulation. Merge is the difference between PSB0739 and 15 min images. Lost membrane signal due to process retraction in red and new membrane signal from ruffling in blue. Movie 6 shows that local laser damage induces process extension and is blocked by P2Y12R antagonist. Movie 7 show that process extension is restored in the absence of P2Y12R antagonist.

Figure 8: Schema of microglial shape changes and P2Y receptors.

A. Scheme showing the effect of purines of microglial morphologies. Amoeboid and ramified cells are basal microglial states. Microglia change shape between states accordingly to levels of ATP/ADP.

MOVIE LEGENDS

Movie 1: Process extension of an initially amoeboid, tomato lectin labeled microglia from peri-tumoral cortex induced by 10 µM ADP applied at time counter = 10 min. Scale, bottom left. Frame rate 3 per sec.

Movie 2: Membrane ruffling of an initially amoeboid cell from the sclerotic CA1 region of MTLE tissue on application of 2 mM ADP, at time counter = 5.40 min. Followed by process extension when ADP was removed, at time counter = 45.25 min. Scale, bottom left. Frame rate 3 per sec.

Movie 3: Process retraction and membrane ruffling of an initially ramified cell from peri-tumoral cortex induced by application of 2 mM ADP at time counter=7.13 min. Followed by vigorous process
extension when ADP was removed, at time counter = 49.04 min. Scale, bottom left. Frame rate 3 per sec.

**Movie 4:** Process retraction and cessation of surveillance motility of a ramified microglia of peri-tumoral cortex induced by PSB 0739 (1 µM) applied at time counter= 11 min. ADP at 10 µM applied in the presence of PSB0739 at time counter =25 min does not induce process extension. Scale, bottom left. Frame rate 3 per sec.

**Movie 5:** Joint application of P2Y1 (MRS2500, 10 µM) and P2Y13 (MRS2211, 30 µM) antagonists, at time counter =11 min, suppresses ADP-induced (2 mM) process retraction of an initially ramified microglia from the dentate gyrus of an MTLE tissue. ADP applied at time counter = 30.00 min. Scale, bottom left. Frame rate 3 per sec.

**Movie 6:** Laser-induced tissue damage induces process extension by an initially amoeboid microglia of peri-tumoral cortex. Red circle indicates laser damage. First laser stimulus at time counter=2.59 min. PSB 0739 (1 µM) was applied at time counter=16.59 min. Second laser stimulus of the same intensity at the same site, at time counter=21.59 min. Scale, bottom left. Frame rate 3 per sec.

**Movie 7:** Two laser stimuli at interval 7 minutes, both induce process extension by 2 initially amoeboid and 1 ramified microglia of peri-tumoral cortex. The green arrow points to the targeted region and the red circle indicates the visible extent of damage. First laser stimulation at time 3.00 min and the second at time counter 10.37 min. Scale, bottom left. Frame rate 3 per sec.

**ACKNOWLEDGEMENTS**

This work was supported by grants from the European Research Council (322721 ERC-senior, RM), ERAnet Neuron (ANR-12-NEUR-0002-03, RM). Technical platforms at the ICM are supported by Investissements d’Avenir (ANR-10-IAIHU-06) and NeurATRIS (ANR-11-INBS-0011).

**REFERENCES**

http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=52


